Product Categories
| Country: | China |
|---|---|
| Tel: | 177-54423994 |
| Mobile: | 17754423994 |
| E-mail: | 2853530910@QQ.com |
| QQ: | 2853530910 |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Keliximab | 174722-30-6 | Details |
| 1-(2-Methoxy-5-methylphenyl)ethanone | C10H12O2 | 20628-07-3 | Details |
| Motavizumab | 677010-34-3 | Details |
| NGB2904 | C28H29Cl2N3O | 189060-98-3 | Details |
| Apolizumab | 267227-08-7 | Details |
| JTE-607 dihydrochloride | C25H32Cl3N3O5 | 188791-09-5 | Details |
| Pax2 inhibitor EG1 | C22H18N2O5 | 693241-54-2 | Details |
| Lenacapavir | C39H32ClF10N7O5S2 | 2189684-44-2 | Details |
| NNMTi | C10H11N2.I | 42464-96-0 | Details |
| Meplazumab | 2413715-21-4 | Details |
| NSC 2805 | C14H14O4 | 4371-34-0 | Details |
| JHN76359 | C25H19NO4S2 | 1715076-35-9 | Details |
| Caroverine hydrochloride | C22H27N3O2 | 55750-05-5 | Details |
| Tuvirumab | 138660-97-6 | Details |
| 2-(Pyrrolidin-1-yl)acetic acid hydrochloride | C6H12ClNO2 | 6628-74-6 | Details |
| Basiliximab | 179045-86-4 | Details |
| LM11A-31 dihydrochloride | C12H26ClN3O2 | 1243259-19-9 | Details |
| (2S,1'R,2'S)-N-(tert-butoxycarbonyl)-2-(1'-hydroxy-2'-Methyl-3'-butenyl)-pyrrolidine | C14H25NO3 | 159173-40-7 | Details |
| Cl-Amidine | C14H19ClN4O2 ? CF3CO2H | 1043444-18-3 | Details |
| AAL-993 | C20H16F3N3O | 269390-77-4 | Details |
| CC-885 | C22H21ClN4O4 | 1010100-07-8 | Details |
| UoS12258 | C17H19FN2O2S | 875927-64-3 | Details |
| RG7834 | C22H27NO6 | 2072057-17-9 | Details |
| 5-hydroxy-3,9-dimethyl-7H-benzo[c]fluoren-7-one | C19H14O2 | 80826-37-5 | Details |
| iBET-BD1 | C30H33N5O3 | 2451862-42-1 | Details |
| SCO-267 | C36H46N4O5 | 1656261-09-4 | Details |
| Foravirumab | 944548-38-3 | Details |
| Galiximab | 357613-77-5 | Details |
| Pascolizumab | 331243-22-2 | Details |
| Siplizumab | 288392-69-8 | Details |
| AZ10606120 dihydrochloride | C25H34N4O2.2HCl | 607378-18-7 | Details |
| Visilizumab | 219716-33-3 | Details |
| JNJ38877605 | C20H12F2N6 | 943540-74-7 | Details |
| CAROVERINE | C22H27N3O2 | 23465-76-1 | Details |
| dupilumab | 1190264-60-8 | Details |
| ONC206 | C23H22F2N4O | 1638178-87-6 | Details |
| Giredestrant tartrate | C31H37F5N4O7 | 2407529-33-1 | Details |
| Narsoplimab | 2108782-45-0 | Details |
| Pexelizumab | 219685-93-5 | Details |
| Bisindolylmaleimide VIII Acetic Acid Salt | C24H22N4O2 | 138516-31-1 | Details |
| Hydroxyibuprofen | C13H18O3 | 51146-55-5 | Details |
| N-(2-Aminoethyl)-2-(2,6-dichlorophenoxy)propanamide | C11H14Cl2N2O2 | 344443-16-9 | Details |
| Briakinumab | 339308-60-0 | Details |
| ONC-212 | C24H23F3N4O | 1807861-48-8 | Details |
| Abemaciclib Metabolites M2 | C25H28F2N8 | 1231930-57-6 | Details |
| Ganitumab | 905703-97-1 | Details |
| VAL083 | C6H10O4 | 23261-20-3 | Details |
| Felvizumab | 167747-20-8 | Details |
| Clenoliximab | 182912-58-9 | Details |
| Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate | C12H11NO4 | 103195-35-3 | Details |
| TNKS656 | C27H34N4O5 | 1419949-20-4 | Details |
| GV-58 | C18H26N6OS | 1402821-41-3 | Details |
| Amatuximab | 931402-35-6 | Details |
| PRL-3 Inhibitor I | C17H11Br2NO2S2 | 893449-38-2 | Details |
| Bavituximab | 648904-28-3 | Details |
| ((4S,5S)-Cy2-Ubaphox)Ir(COD)]BARF | C77H67BF24IrNO2P | 880262-14-6 | Details |
| SU4984 | C20H19N3O2 | 186610-89-9 | Details |
| Rafivirumab | 944548-37-2 | Details |
| Zinpyr-1 | C46H36Cl2N6O5 | 288574-78-7 | Details |
| Cedelizumab | 156586-90-2 | Details |
| RVX297 | C24H29N3O4 | 1044871-04-6 | Details |
| sulfopin | C11H20ClNO3S | 2451481-08-4 | Details |
| ((2-Fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane | C29H42BFO4Si | 2621932-37-2 | Details |
| Pimethixene | C19H19NS | 314-03-4 | Details |
| 2H-Indol-2-one, 1,3-dihydro-3-(4-hydroxyphenyl)-3-[4-(trifluoromethoxy)phenyl]-7-(trifluoromethyl)-, (3S)- | C22H13F6NO3 | 2407860-34-6 | Details |
| Pimethixene maleate | C23H23NO4S | 13187-06-9 | Details |
| PF-05231023 | C26H32N4O8 | 1037589-69-7 | Details |
| F-901318 | C28H27FN6O2 | 1928707-56-5 | Details |
| Vodobatinib | C27H20ClN3O2 | 1388803-90-4 | Details |
| Senaparib | C24H20F2N6O3 | 1401682-78-7 | Details |
| LY 2979165 | C13H17N5O5S | 1311385-35-9 | Details |
| Efalizumab | 214745-43-4 | Details |
| HJC0197 | C19H21N3OS | 1383539-73-8 | Details |
| Labetuzumab | 219649-07-7 | Details |
| Tolebrutinib | C26H25N5O3 | 1971920-73-6 | Details |
| Indirubin-3'-oxime | C16H11N3O2 | 667463-82-3 | Details |
| AZD-0284 | C21H18F6N2O5S | 2101291-07-8 | Details |
| MT802 | C41H41N9O8 | 2231744-29-7 | Details |
| CLK-IN-T3 | C28H30N6O2 | 2109805-56-1 | Details |
| NI-42 | C18H15N3O3S | 1884640-99-6 | Details |
| Dot1L-IN-4 | C28H27ClF2N8O5S | 2565705-02-2 | Details |
| Simufilam | C15H21N3O | 1224591-33-6 | Details |
| PTI-125 hydrochloride | C15H22ClN3O | 2480226-07-9 | Details |
| Lintuzumab | 166089-32-3 | Details |
| Tadocizumab | 339086-80-5 | Details |
| N-[4-(6-Fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide | C23H29FN2O | 1009344-33-5 | Details |
| IWP-4 | C23H20N4O3S3 | 686772-17-8 | Details |
| Ilginatinib | C21H20FN7 | 1239358-86-1 | Details |
| PIM1-IN-1 | C25H30N8O2 | 1417630-95-5 | Details |
| Lumiliximab | 357613-86-6 | Details |
| Sacituzumab | 1796566-95-4 | Details |
| Spongosine | C11H15N5O5 | 24723-77-1 | Details |
| (6R)-FR054 | C14H19NO8 | 35954-65-5 | Details |
| Gevokizumab | 1129435-60-4 | Details |
| HT-61 | C26H24N2O | 936622-80-9 | Details |
| BAY85-8501 | C22H17F3N4O3S | 1161921-82-9 | Details |
| Elinzanetant | C33H35F7N4O3 | 929046-33-3 | Details |
| GSK840 | C21H23N3O3 | 2361146-30-5 | Details |
| Siltuximab | 541502-14-1 | Details |
| LM11A-31 | C12H25N3O2 | 289475-77-0 | Details |
| Product Total： Product Page： | ||||
| 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 | ||||